A non-canonical base pair within the human immunodeficiency virus Rev-responsive element is involved in both Rev and small molecule recognition  by Werstuck, Geoffrey et al.
A non-canonical base pair within the human 
immunodeficiency virus Rev-responsive element is 
involved in both Rev and small molecule recognition 
Geoffrey Werstuck’, Maria L Zapp* and Michael R Green’* 
‘Program in Molecular Medicine, Howard Hughes Medical Institute, UMASS Medical Center and 2Department of Molecular Genetics 
and MicrobiologykJMASS Cancer Center, Worcester, MA, 01605, USA 
Background: Human innnunodeficiency virus (HIV) 
replication depends on the interaction of an HIV regula- 
tory protein, Rev, with a viral RNA element (the Rev- 
responsive element, RRE). The high affinity RRE core 
region contains a non-canonical base pair (G48:G71) that 
is important for Rev recognition. Aminoglycoside anti- 
biotics, specifically neomycin B, bind to the RRE and 
selectively block Rev-RRE interactions in viva and in 
vitro. We attempted to generate an itz vitro model for the 
establishment of HIV-1 resistance to neomycin B. 
Results: We have used in vitro genetic selection to evolve 
RRE variants that bind to Rev in the presence of 
neomycin B. Most of the RRE variants selected in the 
presence of 10 FM neomycin B contain a G48:G71 to 
A48:A71 substitution. Those selected in 100 FM 
neomycin B contain either C:A or A:A substitutions at 
this position. Binding constants for the interaction of 
neomycin B with the wild-type RRE and a subset of the 
selected RRE variants were determined using a novel 
ultrafiltration procedure. 
Conclusions: A purine-purine base pair within the bulge 
region of the RRE core element is critical for neomycin B 
binding as well as Rev binding. RF@ variants that survive 
in high concentrations of neomycin do so either by 
binding Rev better than wild-type (this correlates with the 
sequence A48:A71) or by binding neomycin poorly (corre- 
lating with the sequence C48A71). Other sequences must 
also influence both Rev and neomycin B binding. 
Chemistry & Biology February 1996, 3:129-l 37 
Key words: in vitro selection, neomycin B, Rev, RRE 
Introduction 
Productive HIV infection is dependent on the interac- 
tion of the regulatory protein, Rev, with a specific RNA 
structure known as the Rev-responsive element or RRE 
(reviewed in [l]). The RRE is a 234-nucleotide RNA 
sequence embedded within the viral env coding region. 
The high affinity Rev binding site, or core element, 
within the RRE consists of a stem-bulge-stem structure 
corresponding to stem IID and stem-loop IIB of RRE 
of such therapy, however, is that the virus may rapidly 
evolve drug-resistant strains. HIV-l is notorious for the 
‘malleability’ observed when it develops resistance to 
small molecules that target HIV reverse transcriptase [14] 
or protease ]15]. 
Neomycin B and other aminoglycoside antibiotics can 
block the Rev-RRE interaction in vitro and in vivo, by 
binding to the RRE core [ 161. RNA-binding drugs such 
domain II (Fig. 1, [2-5]).Th e intervening bulge region is 
predicted to contain two non-Watson-Crick base pairs, 
G48:G71 and G47:A73 [6-S]. 5’ 
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3’ CGCA IID Rev activates env expression by facilitating the redistri- 
bution of unspliced and singly spliced HIV mRNA out of Stem “G/yU* / 
50 Stem-loop 
the nucleus by a mechanism that is not fully understood IIA 
[9,10]. Because the Rev-RRE interaction is essential for loo’ 
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viral replication, and is known to limit replication in 
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some circumstances [9,10], Rev is an attractive target for 
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antiviral therapy. Several strategies have been attempted 
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to reduce intracellular Rev levels or to block its func- 
tion. These include, for example, the expression of anti- 
;s, $$‘,o 
sense nucleic acids directed against Rev mRNA [ll], 
U ‘AC \ I 
A A Core element 
dominant-negative Rev mutants 12,121, and Rev-specific “uA 
single-chain antibodies [13]. 
Small molecules can be useful antiviral agents because 
Fig. 1. Domain II of the HIV RRE. Vertical lines indicate base 
they are relatively easy to deliver. One potential limitation 
pairing within the RRE core element and the G48:G71 base pair 
is outlined. 
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as neomycin B are thus attractive lead compounds for 
antiviral therapies. But is it possible to generate muta- 
tions within the RRE that retain Rev binding but are 
resistant to neomycin B inhibition? Here we use an in 
vitro selection technique [17-191 to mimic the evolution 
of neomycin B-resistant RREs. We find that neomycin- 
resistant RNAs can evolve in two ways, either by increas- 
ing their affinity for Rev or by decreasing their affinity 
for neomycin B. At high concentrations of drug, the 
latter mechanism appears to be more important. 
Results 
Selection for neomycin resistance leads to changes at the 
C48:C71 base pair 
We initiated the selection with a previously described 
RNA pool that was biased toward the wild-type (WT) 
RRE [20]. The pool contains 1013 variants of the 67 
nucleotides of domain II of the WT RRE, and was con- 
structed such that each base had a 65 % chance of being 
WT, 30 % chance of being substituted, and a 5 % chance 
of being deleted. 
Neomycin B concentrations of 0.1 to 1 PM can quanti- 
tatively inhibit Rev binding ([ 161, this study). We carried 
out three separate selections, using 0, 10 or 100 p,M 
neomycin B. In each selection, RNA molecules bound to 
Rev were separated from unbound sequences by a com- 
bination of nitrocellulose-filter binding and mobility-shift 
gel electrophoresis. Bound RNAs were eluted, amplified 
by the reverse-transcriptase polymerase chain reaction 
(RT-PCR), and transcribed into RNA. A total of nine 
rounds of selection and amplification were carried out 
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Fig. 2. The sequences of RRE variants 
selected in the presence or absence of 
neomycin B. Pools N,, N,, and N,,, 
were selected for Rev binding in the 
presence of 0, 10 and 100 FM 
neomycin B, respectively. The sequences 
are aligned with the RRE domain II 
region (WT). Nucleotides are numbered 
according to Malim et al. [2,3]. Bases 
that differ from the WT sequence are 
indicated, bases that correspond to WT 
are designated by a period (.) and 
deleted bases are indicated by a dash 
(-). Within each pool, the sequences are 
grouped according to the identity of the 
48:71 base pair. All of the selected 
sequences contain two relatively con- 
served blocks of sequence (shaded) that 
correspond to the RRE core domain 
upon folding. RRE variants, especially 
those selected in the presence of 
neomycin B (N,, and N,,,), diverge 
from the WT sequence at positions 48 
and 71, which corresponds to the G:G 
base pair within the WT RRE core 
region. Sequences selected in 10 FM 
neomycin B predominantly contain 
A48:A71 while those selected in the 
presence of 100 )*M neomycin B 
contain either an A:A or C:A base pair at 
this position. The DNA sequence is 
given here; for the RNA sequence, read 
U for T. 
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and members of each pool were sequenced at various 
stages during the selection. 
Two characteristics of the selected RRE variants are 
evident upon comparison with the WT RRE (Fig 2). 
First, all of the selected sequences contain two relatively 
conserved blocks of sequence that correspond to the 
RRE core domain. Sequences outside of the core 
element, especially those corresponding to stem IIA and 
stem-loop IIC, diverge greatly from WT.This is expected 
since the RREs were selected by virtue of their affinity 
for Rev. Second, RRE variants selected in the presence 
of 10 FM neomycin B (N,,) and 100 PM neomycin B 
(N,,,), diverge from the WT sequence, at positions 48 
and 71, and these bases seem to covary. 
The covariation of bases 48 and 71 supports a large body 
of evidence that a purine-purine base pair is required at 
this position for efficient Rev binding [20-221. Of the 17 
sequences determined from the N, pool, 10 are 
G48:G71 (WT) and 6 are A48:A71.TheA:A substitution 
has previously been shown to support Rev binding 
[20,21]. Selection in the presence of neomycin B appears 
to strongly favor RRE variants containing A48:A71 or 
C48:A71; 75 % of the N,,, pool sequences contain an 
A:A at this position and the Ntoo pool consists of a 
mixture ofA:A (39 %) and C:A (35 %) containing vari- 
ants. Remarkably, none of the N,, or N,,, RNAs 
contain a G48:G71 base pair. 
Neomycin B sensitivity of individual RRE variants 
Binding of Rev and neomycin B is competitive [16] and 
thus our selection procedure will identify RNAs that are 
better able to discriminate between Rev and neomycin 
than the original pool. Improved discrimination could 
occur because the affinity for Rev has increased, the 
affinity for neomycin B has decreased, or both. We there- 
fore examined the affinity of each variant for Rev in the 
absence of drug (Table l), and chose representative 
members from each of the three pools to examine in 
binding assays with Rev in the presence of 0, 10 or 
100 PM neomycin B. 
Figure 3a shows that each N, RNA tested was sensitive to 
neomycin B inhibition in a dose-dependent manner; inhi- 
bition was greater at 100 PM than 10 FM drug. Some of 
these N, RNAs were less sensitive than the WT RRE to 
neomycin B, probably due to their higher affinity for Rev. 
The RNAs from the N,, pool were much less sensitive 
than the WT RRE or the N, RNAs to neomycin B inhi- 
bition (Fig. 3b); binding of the N,, RNAs to Rev in 10 
or 100 FM neomycin B was generally comparable. Like 
the N, RNAs, all but one of the N,, RNAs (N,,-21) 
bound Rev with a higher affinity than did the WT RRE. 
All of the NIOO RNAs were neomycin B-resistant (Fig. 
3~); Rev binding was comparable in drug concentra- 
tions from 0 to 100 PM. Unlike the N, and N,, RNAs, 
the NlOO RNAs bound to Rev with a wide range of 
Table 1. Comparison of Rev and neomycin B binding affinities. 
RRE Position KdNeo Kd RW Kd NW 
varianta 48:71b (nMF (nMJd --iG- Kd 
WT RRE G:C 82 +3 1 .o 82 
RRE-AA A:A 230 *20 0.7 kO.2 330 
RRE-CA C:A 320 *30 1.4 *O.l 230 
N,-16 G:G 20 +3 0.4 50.3 50 
N,-25 A:A 0.5 kO.6 
N,-19 G:G 0.5 +0.4 
N,-14 A:A 0.5 *O.l 
N,-18 G:C 0.5 *O.l 
N,-31 A:A 0.6 +O.l 
N,-32 G:G 0.6 kO.1 
N,-30 G:G 0.8 *0.3 
N,-13 A:C 61 i6 0.8 +0.2 76 
N,,-23 A:A 28 *l 0.4 *0.3 70 
N,,-16 A:C 53 +24 0.5 kO.5 110 
N,,-14 A:A 0.7 kO.5 
N10-3 A:A 0.6 i0.6 
N,,-19 A:A 0.6 kO.6 
N,,-20 A:A 160 *20 0.6 kO.5 270 
N,,-21 A:- 810 +80 3.2 kO.1 250 
N 100-j' C:A 180 +40 0.4 kO.3 450 
N,oo-35 A:A 0.5 kO.2 
N 100 -1 A:A 92 +9 0.7 +0.4 130 
N 100 
, ,,:364 
C:A 120 +30 
N A:A 0.8 +0.2 
N 
;;;:;; :i; 
560 k270 0.8 kO.3 700 
N 
N 
N ;;;:;; :.“, 
720 +I90 1 .I kO.3 650 
990 *300 1.6 kO.1 620 
450 +I40 3.3 +0.2 110 
N ,oo-26 U:G 450 +60 4.3 *O.l 100 
N,,,-22GG G:G 110 *lo 0.8 kO.1 140 
N ,,-26GG G:G 60 *7 4.0 +0.2 15 
aRRE variants are listed within each pool according to 
decreasing affinity for Rev. 
bldentity of bases 48 and 71 when the variant sequences are 
positioned to give maximum alignment with the wt RRE. 
‘Binding constants (shown as the mean value + the standard 
error of the mean of at least four independent experiments) 
were determined using the ultrafiltration/NPT II assay. 
dEstimate derived from the K, of Rev for the WT RRE (1 nM 
[36,371) divided by the Rev-binding ratio (see Materials and 
methods). Reported K, values for the Rev-WT RRE interaction 
range from 0.3 to 15 nM. 
affinities, and, surprisingly, several (NtO,,-13,16,21,22 and 
26) bound less well than the WT RRE. 
Together, these results indicate that the RREs selected in 
the presence of neomycin B (pools N,, and N,,,) were 
refractory to neomycin B inhibition, whereas RRE 
sequences selected in the absence of drug (pool No) 
retained sensitivity. 
Role of the 48:71 base pair in neomycin B resistance 
We next examined whether the increased resistance of 
the neomycin B-resistant variants is due to the substitu- 
tion at positions 48:7 1. We used RRE variants containing 
the point mutations A48:A71 (RRE-AA) and C48:A71 
(RRE-CA) in an otherwise WT background (Fig. 3d). In 
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Fig. 3. Rev binding to RRE variants in the presence of 0, 10 and 100 FM neomycin B. Individual RRE variants were tested for their sensitiv- 
ity to neomycin B inhibition of Rev binding. 32P-labeled RRE variants were incubated with Rev and various concentrations of neomycin 6. 
Bound RNA was isolated by nitrocellulose filter binding and quantitated by scintillation counting. Binding of the WT RRE is compared to 
individuals selected from (a) pool N,, (b) pool N,,, (c) pool N,,, and (d) the RRE mutants RRE-AA and CA (point mutants consisting of the 
WT RRE sequence with a C48:G71 to A:A or C:A substitution). Each data point represents an average of three independent experiments. 
the absence of drug, Rev bound with a 1.5 fold higher 
affinity to RRE-AA than to the WT RRE, and RRE- 
CA had the lowest relative affinity for Rev. In 10 p,M 
neomycin B, the relative affinity of Rev for RRE-AA 
increased only slightly - not enough to explain the pre- 
dominance ofA48:A71, and the lack of G48:G71, in the 
variants in the N,, pool. In 100 p,M neomycin B, binding 
of Rev to the WT RRE and to RRE-AA was effectively 
blocked. Most importantly, in 100 PM neomycin B, 
RILE-CA retained significant Rev binding activity. 
Thus, the identity of the 48:71 base pair in the wild-type 
background can be important for both Rev binding and 
neomycin B sensitivity. In particular, an A48:A71 base pair 
increases Rev affinity but does not greatly affect neomycin 
B sensitivity. A C48:A71 base pair modestly decreases affin- 
ity for Rev but d ramatically decreases neomycin B sensi- 
tivity.The results of Figure 3d explain the preponderance 
of C48:A71 variants in the N,,(, pool (see Fig. 2). 
A novel assay for quantitating neomycin B-RNA interactions 
The RNA binding data (Fig. 3) clearly show that sequences 
outside the core region are also involved in neomycin B 
resistance. For example, No-14 contains an A48:A71 substi- 
tution but is significantly less sensitive to neomycin B than 
RILE-AA. Furthermore, N,,, RNAs such as N,,,,,-16, 
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which contains the C48:A71 base pair, and N,,,,,-35, which 
contains the A48:A71 base pair, are more resistant to 
neomycin B inhibition than would be expected from this 
one mutation alone (compare Fig. 3c and Fig. 3d). These 
results suggest that neomycin B resistance can be affected by 
sequence elements other than the base pair at 48:71. 
To test this idea directly, binding constants were deter- 
mined for the interaction of neomycin B with individual 
RRE variants.The small size of the drug relative to RNA 
permits the use of an ultrafiltration technique [23-261 to 
separate the free and RNA-bound forms of the drug 
(Fig. 4). Bound and free neomycin B concentrations were 
quantitated by radiolabeling with [Y~~P]-ATP and 
neomycin phosphotransferase II (NPT II) [27]. 
Figure 5a shows that binding of drug to the WT RRE 
is saturable when -80 % of the RNA is bound. Under 
identical conditions, very little Esckevickia coli tRNA 
was bound by drug, indicating that interaction with 
neomycin B is specific, consistent with previous results 
[16]. A Scatchard plot reveals a single neomycin B 
binding site in the WT RRE, with a K, of 82 nM (Fig. 
5b). Consistent with this result, previous studies have 
shown that under some conditions neomycin B inhibits 
Rev binding at concentrations as low as 100 nM ([16] 
and data not shown), and that 100 nM neomycin B 
protects the RRE from chemical attack [16]. 
Affinity of neomycin B for WT RRE and variants 
Is the increased resistance to neomycin entirely, or only 
partially, due to changes in the affinity of the RNA for 
the drug? The N, pool RRE variants were sensitive to 
neomycin B inhibition (Fig. 3a) and therefore are pre- 
dicted to have a relatively high affinity for the drug.The 
two N, RNAs tested (No-16 and N,,-13) did indeed 
have a slightly higher affinity for neomycin B than the 
WT RRE.These variants also bound Rev with higher 
affinity than that ofWT (estimated K, values of 0.4 and 
0.8 nM, respectively; see Table 1). 
In contrast, the N,, pool RREs were relatively resistant 
to neomycin B inhibition (Fig. 3b). In these RNAs, two 
Fig. 5. Determination of the Rev-RRE 
binding constant. Ultrafiltration was 
used to separate free neomycin B from 
binding solutions containing the RRE 
variant RNA (or tRNA) and various con- 
centrations of neomycin B. Bound and 
free drug concentrations were deter- 
mined relative to standards using a 
neomycin phosphotransferase II (NPT II) 
assay. Representative data from a typical 
experiment are plotted in the form of (a) 
a saturation curve and (b) a Scatchard 
plot. The K, values for the WT RRE 
(82 + 3 nM), RRE-AA (230 f 16 nM) 
and RRE-CA (320 & 27 nM) were deter- 
mined by least-squares analysis of at 
least four independent experiments. 
f 
C&t 
Fig. 4. Summary of the procedure used to determine neomycin B 
binding constants. Binding reactions containing O-800 nM 
neomycin B and O-200 nM RRE (or RRE variant) were partitioned 
by ultrafiltration through a 10 000 MW cut-off filter into fractions 
containing both free and RNA-bound neomycin 6 or free 
neomycin B alone. The neomycin B in each fraction was radio- 
labeled in a reaction with [Y~~P]-ATP and NPT II [27]. 
Radiolabeled neomycin B was isolated on P81 paper and quanti- 
tated by scintillation counting. The red lines represent the RRE 
variant RNAs and the blue asterisks represent neomycin B. 
mechanisms for resistance were evident: N,,,-23 and 
Nr,,-16 both showed somewhat higher affinity Rev 
binding than WT RRE, but bound neomycin B with 
K, values similar to WT (Table 1). Thus, these RNAs 
were selected in 10 ~.LM drug by virtue of their high 
affinity for Rev (KdReV of 0.4 and 0.5 nM, respectively). 
In contrast Nr,,-21 had a relatively low affinity for Rev 
(KdReV of 3.2 nM), most probably resulting from dele- 
tion of the base at position 71. But Nr,,-22 was even 
more severely compromised for binding to neomycin B 
(Kd = 810 nM). For all of these RNAs except N,,,-23, 
the level of discrimination between neomycin and Rev 
was higher than that ofWT. 
[Neomycin B] (nM) 
0 
- 
=: kc x 
[Bound] (nM) - 
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In general, the neomycin B binding constants for the 
N ioo RNAs were higher than those for the N, or N,, 
RNAs, ranging from 92 to 990 nM, and a wide range of 
Rev binding constants was observed (estimated K, 
values of 0.4-4 nM). N,,,-31 and N,,,-1, which bound 
Rev with high affinity (estimated K, values of 0.4 and 
0.6 nM) also had the highest affinity for neomycin B 
(Kd values of 180 and 92 nM, respectively). The variants, 
N,,,-22, 16, 21 and 26, all of which bound Rev less 
well than the WT RRE, also had significantly lower 
affinity for neomycin B (Kd values of 560,720,450, and 
450 nM, respectively). 
RRE variants selected in the presence of 100 PM 
neomycin B thus generally had a lower affinity for the 
drug than those selected in 0 or 10 I.LM neomycin B. 
Again, it was possible to see the effect of either enhanc- 
ing Rev binding without decreasing neomycin binding 
(N,,,-1) or decreasing neomycin binding without affect- 
ing Rev binding (N,,,- 13,22). However, it seems to be 
hard to generate large decreases in neomycin binding 
without some change in Rev binding. For example, 
N,,,-16,21,26 and N,,-21 all seem to have paid a price 
in Rev affinity for their decreased neomycin affinity. 
The Scatchard data suggested that all but two of the RRE 
variants contain a single neomycin B binding site.These 
two exceptions, N,,,-16 and N,,,-22, had a relatively low 
affinity for neomycin B and, when the drug concentration 
was high enough for binding to be observed, more than 
one molecule of neomycin B was seen to bind (see Fig. 
6). We imagine that at these high concentrations binding 
of the drug is relatively non-specific. 
A G48:C71 substitution increases neomycin B affinity 
The RRE-AA and RRE-CA point mutants show three- 
to four-fold decreases in binding to neomycin compared 
to wild-type (Table l), while the selected mutants con- 
taining the A:A base pair have affinities ranging from 
three-fold higher than wild-type to two-fold lower, and 
the C:A mutants range from 1.5 to 1 l-fold lower than 
wild-type. Once again, it is clear that the identity of the 
48:71 base pair is not the only factor that determines 
affinity for neomycin B.To determine the relative impor- 
tance of this base pair compared to the other changes in 
the variant sequences, we constructed two additional 
variants. N ,,,-22GG contains a G48:G71 base pair in 
the Nloo- 22 background, instead of the selected C:A 
base pair, and N,,,- 26GG contains a U48:G71 to G:G 
substitution within the N,,,-26 background. In the 
N,,,-22 variant the C48:A71 to G:G substitution 
decreased the K, for neomycin B from 720 nM to 
110 nM. In the N 100-26 background, the U:G to G:G 
change decreased the K, for neomycin B from 450 nM 
to 60 nM (Table 1). Mutations in this base pair, in either 
of these variant backgrounds, can thus cause a change in 
the affinity of the RNA for neomycin B of about seven- 
fold. This one change can account for essentially all of 
the differences in neomycin affinity between the variants 
and wild-type RRE. As expected from these data, 
2 R :: 0 
[Bound] (nM) 
t-4 
- [Bound] (nM) 
Fig. 6. Representative Scatchard plots of neomycin B binding to 
N,,, RRE variants containing a C48:G71 substitution. A 
G48:G71 base pair was introduced into the N,,, pool variants, 
N,,,-22 (formerly C:A) and N ,an-26 (formerly U:G). This single 
base pair substitution shifts the Kd; (a) from 720 * 190 nM 
W ,,,e-22) to 110 f 10 nM (N,,,-22GG) and (b) from 
450 f 60 nM (N ,e0-26) to 60 f 7 nM (N,,,-26), respectively. 
N,,,-22GG and -26GG are sensitive to drug inhibition 
(data not shown). 
The change in the 48:71 base pair in these variant back- 
grounds has a negligible effect on Rev binding (Table 1). 
Significantly, although variant N,,,-22 seems to bind 
neomycin B at multiple sites (see above), N,,,-22GG has 
a single, higher affinity binding site, consistent with the 
notion that a purine-purine base pair is an important 
component of the high-affinity neomycin-binding site. 
Discussion 
Neomycin B is an aminoglycoside antibiotic that com- 
petitively inhibits binding of Rev to the RRE [16]. 
We have used in vitro selection to evolve neomycin 
B-resistant RRE variants from a diverse sequence pool. 
Selection is based on the ability of the RNA to bind to 
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Rev, with the additional selective pressure that the RNA 
variants must bind Rev in the presence of a drug that 
normally blocks this interaction. 
Each of the three selected RNA pools (N,, N,,, N,,,) 
contain distinct sequence characteristics. RRE variants 
selected in the absence of neomycin B (No pool) 
contain the WT G48:G71 or the isosteric A48:A71 base 
pair. The majority of the variants selected in 10 PM 
drug (N,,,) contain A48:A71, while those selected in 
100 p,M drug (N,,,) predominantly contain an 
A48:A71 or C:A base pair at this position.The context 
in which the base pair is found is also important for 
both Rev and neomycin B affmity.These effects could 
result from the disruption or formation of direct con- 
tacts between the RNA and the protein (or drug) or 
from indirect effects of RNA structure. 
Some of the variants from the N,, and N,,, pools 
contain regions of non-WT homology, in particular at 
positions 83-87, that are not found in N, RNAs. For 
example, several of the N,, variants (N,,-3,6,16,21) 
contain the sequence U84G85, whereas N,,, variants 
(N,,,-20,29,34,35) contain the sequence UGGG 
(83-86) and variants N,,,- 16,22,32b contain GGUGG 
(83-87). These bases are located in the loop region of 
stem-loop IIC. Molecular simulation modeling predicts 
that, in the most stable conformation, RRE domain II 
stem-loop IIC and IIB are stacked [28]. This model is 
consistent with the idea that bases in stem-loop IIC may 
affect binding to the RRE core element. 
A comparison of Rev and neomycin B binding to the 
RRE variants from each of the three pools indicates that 
each pool has distinct protein- and drug-binding charac- 
teristics.Variants selected in the absence of drug bound 
to Rev with high affinity but retained their sensitivity to 
neomycin B. In fact, the affinities of No-13 and No-16 
for neomycin B are higher than that of the WT RRE. It 
is possible that high affinity Rev binding sites possess 
characteristics that also facilitate drug binding. Selection 
in the presence of 10 FM neomycin B favored sequences 
that, generally, bound Rev with a higher affinity than the 
WT RRE. These RNAs typically contain an A48:A71 
base pair. One exception is N,,-21, which has a deletion 
of base 71 and binds both Rev and neomycin B poorly. 
Most of the N,,, variants showed decreased neomycin B 
binding affinities, however, suggesting that, for selection 
in the presence of 100 PM neomycin B, a high afhnity 
for Rev is insufficient. 
High affinity Rev binding sites have been identified by 
several groups [20,21,29]. In general, the results suggest a 
requirement for a destabilized stem or bulge region that 
widens the major groove, making it more accessible to 
Rev [7]. The requirements for neomycin B binding are 
less clear although, like Rev, it seems to prefer a bulged- 
helical region in which the major groove is widened 
[30]. CD spectra and RNA footprinting experiments of 
the neomycin B-RRE complex suggest that the drug 
binds within the major groove (L. Ratmeyer et al., per- 
sonal communication, and [16]). Due to its small size, the 
drug is probably limited to relatively few contacts with 
the RRE.Therefore the substitution of a critical base pair 
is predicted to have a greater effect on drug than on 
protein binding.This is consistent with the finding that 
neomycin B binding is restored to WT levels by a 
G48:G71 substitution in the N,,,()-22 and N,,,,-26 RREs. 
Neomycin B binds to a number of RNAs in addition to 
the HIV RRE, including, prokaryotic ribosomal RNA 
[31], group 1 introns [32] and hammerhead ribozymes 
[33]. Artificial, high affinity neomycin-binding RNAs 
have been selected from random RNA pools ([30], G.W. 
and M.R.G., in preparation). Together, these studies 
suggest that neomycin B can recognize and bind to a 
wide variety of RNAs that seem to be unrelated in 
terms of primary sequence. Our results suggest that 
neomycin B recognizes the primary as well as the sec- 
ondary and/or tertiary structure of RNA. Substituting 
A48:A71 for the WT G:G base pair in the WT back- 
ground increased the K, for neomycin B 2.8-fold, sug- 
gesting that the drug may directly contact these residues, 
and does not merely recognize the structure of the 
bulged backbone that results from the purine-purine 
base pair. This is consistent with the observation that 
neomycin B protects the Nl and/or N2 positions of 
G48 in RNA footprinting experiments [16]. 
Significance 
We have probed the ability of Rev to interact 
with RRE variants that are insensitive to a 
potential anti-viral drug therapy. Our data 
suggest that neomycin B recognizes and binds 
to an RNA sequence (or structure) similar to 
that bound by Rev. Thus, variants that are highly 
neomycin B-resistant generally show decreased 
affinity for Rev. This may compromise replica- 
tion of a virus harboring a neomycin B-resistant 
RRE variant. Additional constraints may further 
limit the acquisition of drug resistance. For 
example, two known constraints are maintenance 
of a functional env open reading frame and the 
conservation of RRE sequences that interact 
with cellular factors required for Rev and other 
functions [34]. 
This study shows that an in vitro genetic selection 
technique can be used as a model to measure the 
emergence of drug resistance. This approach is 
especially useful in the study of highly mutable 
viruses such as HIV and could be applicable to 
other potential drug targets. The ability to make 
predictions about how a target molecule might 
mutate to become resistant to a potential thera- 
peutic could further our understanding of the 
basis of the interaction in question and assist in 
the rational design of newer, more effective drugs. 
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Materials and methods 
Protein and RNA 
Rev protein was over-expressed and purified from E.coli as 
described by Zapp et al. [35]. Construction of the initial DNA 
pool containing 1013 dRRE domain II variants (pool 0) is 
described in Bartel et al. [20]. The WT RRE domain II was 
transcribed from the Hi&II linearized plasmid pGEMZ-94.7 
[16]. RRE point mutant RRE-AA, -CA, N,,,-22GG and 
N,,e-26GG were synthesized as single-stranded DNA 
oligonucleotides. They were PCR amplified with flanking 
primers and transcribed using T7 RNA polymerase. 
In vitro RNA selection 
Binding reactions for selection were set up as follows: Rev, 
tRNA and the appropriate concentrations of neomycin B 
(ICN) were pre-incubated at room temperature (RT) for 
10 nun in 25 ~1 of 40 mM Tris, pH 7.9, 50 mM KCl, and 
1 mM dithiothreitol (DTT) (binding buffer, BB). Pool RNA in 
25 p.1 of BB was incubated at 80 “C for 3 min and then at RT 
for 7 min. The RNA and protein/drug solutions were then 
mixed together (giving final concentrations of 30 nM Rev, 
0.1 mg ml-’ tRNA, 0.4 PM RRE pool in 50 ~1 BB) and incu- 
bated 1 h at 30 “C. Rev bound RNA was separated from 
unbound sequences by nitrocellulose filter binding (selection 
rounds 1,2,3,5,7,9) or by mobility shift (selection rounds 4,6,8). 
In the filter-binding assay the mixtures were passed 
through HAWP 025 00 nitrocellulose filters (M&pore) under 
vacuum. The filters were washed twice with BB. RNA was 
eluted in PK Buffer (100 mM Tris pH 7.5, 12.5 mM EDTA, 
150 mM NaCI, 1 o/o SDS) at 65 “C for 40 min. Eluents were 
phenol/chloroform extracted, ethanol precipitated and then RT- 
PCR amplified with the primers d40.50 and d22.18 as previ- 
ously described [2O].To separate bound RNA using the mobility 
shift assay binding reactions were loaded onto a 5 o/o poly- 
acrylamide gel (30:1) and run at 250 V for 2.5 h in 0.5 x Tris- 
borate-EDTA. Shifted bands were resolved by autoradiography, 
cut out and eluted in PK buffer while shaking for 1 h at room 
temperature (RT), then amplified as described above. 
RRE pools were digested with EcoRI and HiMdIII and cloned 
into the similarly cut pGEM7Zf+ (Promega) vector. Individual 
clones were sequenced from a T7 primer site within the 
vector. To transcribe the cloned RRE variants the plasmid was 
first linearized with Hind111 and then transcribed with T7 
RNA polymerase. 
Rev binding affinity and neomycin B sensitivity of 
individual clones 
Binding experiments containing final concentrations of 30 nM 
Rev, 0.1 mg ml-’ E.coli tRNA and 0.5 nM WT RRE or RRE 
variant in BB were incubated for 1 h at 30 “C. Rev-bound RNA 
was separated using the filter binding assay (described above). 
Filters were dried and bound RNA was quantitated by scintilla- 
tion counting. The data were expressed in terms of a Rev- 
binding ratio which is equivalent to the amount of RRE variant 
bound divided by the amount ofWT RRE bound, then con- 
verted to estimated Kd values for Rev using a literature value of 1 
nM [36,37] for the WT KdReV. Neomycin B sensitivity was 
determined in similar binding experiments containing 0, 10 or 
100 PM neomycin B. 
RRE point mutants 
The RRE point mutants RRE-AA and RRE-CA were 
synthesized as oligodeoxyribonucleotides containing the 
67-nucleotide sequence from the WT RRE domain II flanked 
by the primer binding sequences TGGGAGCAGCAGGAA 
and TATAGTGCAGCAGCAG at the 5’ and 3’ ends, respec- 
tively. These oligonucleotides were PCR amplified with the 
primers GTAATACGACTCACTATAGGGAATTCTTGGG- 
AGCAGCAGGAA and GCAAGCTTCTGCTGCTGCAC- 
TATA. The PCR products are then transcribed from the T7 
promoter (bold). The point mutants N,,,,,-22GG and 
N,,,(,-26GG were constructed in a similar way but using a 
67-nucleotide sequence corresponding to those of N,,,,,-22 and 
N,,,,,-26, respectively 
Kd determination 
Binding reactions containing O-200 nM unlabeled RRE (or 
RRE variant) RNA, and O-800 nM neomycin B were incu- 
bated at RT for 1 h in 100 ~1 solutions containing 10 mM Tris 
pH 7.6,lO mM MgCl,, 50 mM NH,Cl and 1 mM DTT. Free 
neomycin B was separated from RNA-bound drug by spiri- 
ning the solution for 30 s in a Microcon 10 filter (Amicon). 
Three to ten pl of the flow through (containing free drug) or 
the retentate (containing free and bound drug) were incubated 
in 21 mM Tris malonate pH 7.1, 130 mM NH,Cl, 12.5 mM 
MgCl,, 0.5 mM DTT, 8 pmoles (50 &i) [Y-~‘P]ATP, 1 ng 
neomycin phosphotransferase II (NPT II) (5 prime-3 prime 
Inc., [27]) in a 50 ~1 solution. Reactions were incubated at 
37 “C for 15 min and then 90 “C for 5 min. Solutions were 
extracted with one volume of phenol/chloroform and 3-10 yl 
of the aqueous phase was spotted onto Whatmann 1’81 paper. 
The P81 paper was then washed in ddH,O at 90 “C for 5 min 
followed by 3 washes in ddH,O at RT.The paper was dried and 
counted. Drug concentration was quantitated by scintillation 
counting relative to standards. Bound and free neomycin B 
concentrations were determined and the data plotted as a 
Scatchard plot. 
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